We Don't Own Patient Data–We're Just Babysitting It\n\nBy Lori EllisBioSpace Insights,\n1 days ago\nWhile AI excels at repetitive tasks like triaging medical information calls, document retrieval, and adverse event detection, the industry must address valid concerns from physicians (41% are excited but concerned, according to AMA studies) and patients who distrust AI systems.\n\nIn this episode, IQVIA’s Louise Molloy advocates for complete transparency, including clear disclaimers when AI generates or supports responses, arguing that the industry serves as “custodians, not owners” of patient data with ethical responsibilities.\n\nThis episode is presented in partnership with IQVIA.\n\nHost\nLori Ellis, Head of Insights, BioSpace\nGuest\nLouise Molloy, Associate Director Medical Information & Pharmacovigilance, IQVIA\n\nDisclaimer: The views expressed in this discussion by guests are their own and do not represent those of their organizations.\n\n\nComments \nCommunity Policy\n\nYOU MAY ALSO LIKE\n\nJim DeLillo\n· Followuser · 3.9K followers\nScammers made off with $12.5 Billion\nAI was used to assist with research and editing. The author has no affiliation with any companies mentioned. Wisconsin victims alone lost over $106 million, with imposter scams leading the surge in losses.\n\nEli Lilly Commits $856M in Biobucks to Gate Bioscience for New Class of Medicines\nThe collaboration focuses on ‘molecular gates,’ a class of molecules that the startup company Gate Bioscience says can stop pathogenic proteins from leaving the cell.\n\nBMS, Pfizer Join DTC Trend, Offering Eliquis to Patients for 40% Below List Price\nIn advance of CMS’ negotiated price for the blood thinner taking effect next year, partners Bristol Myers Squibb and Pfizer pitched the direct-to-consumer program as a way to allow uninsured, underinsured and self-pay patients to pay less out of pocket.\n\nLack of US Data Stymie Roche’s Earlier-Stage Lymphoma Push for Columvi\nRoche and Genentech were unable to sufficiently demonstrate the benefit of using Columvi in an earlier treatment setting for DLBCL in a U.S. population, according to the FDA.\n\nNovo Nordisk Names New Leader, Cuts 2025 Sales Guidance By 5%\nIn a surprise double announcement Tuesday, Novo reduced sales guidance by 5%—attributing the change to slowed growth of its semaglutide franchise in the U.S.—and named current international operations head Maziar Mike Doustdar as its new president and CEO.\n\nAfter Moderna Pulled Its Shot, Combination Flu/COVID Vaccines Hang in Limbo\nEarlier this summer the FDA asked Moderna for more efficacy data on its flu vaccine before it could review an mRNA-based combination shot that targets both influenza and COVID-19. Now, the entire vaccine sector is sizing up a new regulatory world, companies’ next steps uncertain.\n\nGSK’s Comeback for Blenrep on Pause as FDA Delays Decision\nThe new target action date for Blenrep, which GSK is proposing for the second-line treatment of relapsed or refractory multiple myeloma, is Oct. 23.\n\nSarepta Up 18% After Business Overhaul as Analysts Cautiously Optimistic\nSarepta Therapeutics appears to have right-sized itself after laying off over a third of its staff, announcing a significant pipeline shift, and adding a black box warning to its Duchenne muscular dystrophy gene therapy Elevidys.\n\nMerck’s $3B Savings Push Claims 6,000 Jobs\nMerck has characterized its cost-cutting initiative as more of a reallocation of resources to support other, higher-growth areas of its business.\n\nGenentech Downsizes by 87 as Priorities Shift\nThe latest round of terminations, which will take effect Sept. 15, comes after Genentech fired more than 500 employees in the last 15 months.\n\nRoche’s Next-Gen Alzheimer’s Antibody Clears or Reduces Amyloid Plaques in Seven Months\nIn a Phase Ib/IIa trial, 91% of patients receiving the highest dose of trontinemab were amyloid negative after seven months of treatment, representing what B. Riley Securities called a “paradigm shift” to first-generation FDA-approved antibodies.\n\nAs Alzheimer’s Space Heats Up, Biopharma Leans In to Holistic Treatment\nAcknowledging the limits of disease-modifying drugs like Leqembi and Kisunla, companies like Bristol Myers Squibb, Acadia, Otsuka and Lundbeck are renewing a decades-old search for symptomatic treatments, including in high-profile drugs like Cobenfy.\n\nReplimmune Plummets Following FDA’s Surprise Rejection of Melanoma Treatment\nBMO Capital Markets pointed to FDA leadership, and CBER Director Vinay Prasad in particular, as potential factors in the agency’s decision to issue a complete response letter for Replimmune’s viral treatment RP1 for advanced melanomas. Shares of the company tumbled 75% on Tuesday.\n\nRocket Trims Headcount and Pipeline Focus Amid Clinical, Regulatory Turbulence\nThe strategic reprioritization comes after the company hit two major hurdles in the past year, including a clinical hold for an investigational gene therapy and an FDA rejection for its lead asset.\n\nOtsuka, Lundbeck Fail To Sway Adcomm on Rexulti Combo for PTSD\nOtsuka and Lundbeck’s data are insufficient to establish significant efficacy of Rexulti plus sertraline in PTSD, according to the FDA’s outside experts.\n\nDenver fentanyl supply tainted with BTMPS\nThe illicit fentanyl supply in Denver and across the U.S. has been tainted with a chemical known as BTMPS, according to Lisa Raville, director of the Harm Reduction Action Center.

We Don't Own Patient Data–We're Just Babysitting It

The article discusses AI's role in healthcare, emphasizing transparency and ethical data ownership concerns. It features IQVIA's Louise Molloy advocating for clear disclaimers in AI-generated medical information. The piece also highlights recent developments in biopharma, including Eli Lilly's $856M investment, BMS/Pfizer's discounted Eliquis program, Roche's FDA decision on Columvi, Novo Nordisk's sales guidance cut, and regulatory challenges for companies like Replimmune and Rocket.